750 TWT-101: a first-in-clinic, phase 1/2 study of CFI-402411, a hematopoietic progenitor kinase-1 (HPK1) inhibitor, as a single agent and in combination with pembrolizumab in subjects with advanced solid malignancies

彭布罗利珠单抗 医学 内科学 胃肠病学 肿瘤科 癌症 免疫疗法
作者
Kyriakos Papadopoulos,Siqing Fu,Erika Hamilton,Alexander I. Spira,Scott A. Laurie,Judy Wang,Brigette Ma,Anna Spreafico,Manish Sharma,Quincy Chu,Mark Bray,Glenn Michelson,Dih-Yih Chen,Linh Nguyen,Emily Roberts-Thomson,Omid Hamid
标识
DOI:10.1136/jitc-2022-sitc2022.0750
摘要

Background

CFI-402411 is a potent inhibitor of HPK1 (Hematopoietic progenitor kinase 1), a protein serine/threonine kinase that negatively-regulates T-cell activation. Following T-cell receptor engagement, HPK1 phosphorylates SLP-76, to down-regulate signals required for T-cell activation and proliferation1,2. CFI-402411 is expected to relieve HPK1-mediated inhibition of T-cell activation, facilitating an anti-tumor immune response.

Methods

In this ongoing phase 1 study, part A evaluates CFI-402411 daily dose in dose escalation cohort (3+3 design) and dose expansion, part B evaluates CFI-402411 in combination with pembrolizumab in dose escalation (BOIN design) and dose expansion in pembrolizumab eligible tumors. Dose limiting toxicity (DLT) is any grade ≥3 toxicity in the first cycle of therapy (21d cycles). Starting dose was 80mg.

Results

As of 14 May 2022 (data cutoff), 25 and 9 patients (pts) enrolled to A and B respectively. Median age was 62 (30-79). Median cycles of treatment were 3 (range: 0-20). Majority of patients were male (A, 60% and B, 78%). Median prior regimens were 2 (range: A, 1-4; B, 1-3). 6pts (A, 24%) and 5pts (B, 56%) received prior anti-PD-1/anti-PD-L1 inhibitor. Diagnoses in ≥2pts for A: colorectal (6pts), pancreatic (5pts); for B: small cell lung cancer (2pts). 8 dose levels (80 to 800 mg) have been studied in A, 2 dose levels (60 and 80 mg) in B. TEAEs occurring in ≥40% of A pts: diarrhea (n=17, 68%), nausea (n=11, 44%), decreased appetite (n=10, 40%); and B: vomiting (n=4, 44%). 19pts (76%) in A and 6pts (67%) in B experienced CFI-402411 related AEs. Immune-related AEs were reported in 1pt (A; 4% [ALT and AST increase]) and 2pts (B; 22% [febrile illness, flu-like symptoms]). Grade ≥3 AEs and serious AEs occurred in 14pts (56%) and 10pts (40%) in A; and 3pts (33%) and 4pts (44%) in B. DLTs occurred in 2pts (A [800mg]: diarrhea, spinal cord compression) and 1pt (B [80mg+pembro]: flu-like symptoms). No novel toxicity signals were seen. Disease control rates were 24% in A (6/25) and 44% in B (4/9). One B patient (11%), squamous head and neck cancer (H&N) previously treated with pembrolizumab, has confirmed partial response (PR) and remains on treatment, 8 cycles. An additional H&N patient treated with monotherapy CFI-402411 achieved unconfirmed PR after data cut.

Conclusions

CFI-402411 is a well-tolerated, potent inhibitor of HPK1 with a manageable AE profile and initial evidence of activity. RP2D and additional safety and efficacy data will be reported at conference presentation.

Acknowledgements

Treadwell Therapeutics would like to thank both the patients and the research staff at enrolling centers who have helped to bring this novel therapy to the clinic.

Trial Registration

NCT04521413

References

Hu MQ. Human HPK1, a novel human hematopoietic progenitor kinase that actives the JNK/SAPK kinase cascade. Genes & Development. 1996;10:2251–2264. Lasserre RC-G. Release of serine/threonine-phosphorylated adaptors from signaling microclusters down-regulates T cell activation. Immuno Res. 2011;295:839–853.

Ethics Approval

This study obtained ethics approvals at the following ethics/IRB's; Papadopoulos, KP; Advarra IRB ID: Pro00051609 Fu, S; University of Texas MD Anderson Cancer Center Office of Human Subject Protection IRB ID 2020-0678 Hamilton, E; Advarra IRB ID: Pro00051611 Spira, A; Advarra IRB ID: Pro00043629 Laurie, S; Ontario Cancer Research Ethics Board, CTO Project ID 3320 Wang, J; Advarra IRB ID: Pro00051611 Ma, B; Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee CREC Ref. No .: 2020.367-T Spreafico, A; Ontario Cancer Research Ethics Board, CTO Project ID 3320 Sharma, M; Advarra IRB: ID Pro00051609 Chu, Q; Health Research Ethics Board of Alberta Ethics ID: HREBA.CC-20-0504_REN1 Hamid, O; WCG, IRB: IRB Tracking Number: 2020236 As evidenced by verified clinical database information all subjects gave informed consent before taking part in this clinical trial.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
Lucas应助小甘采纳,获得10
1秒前
和春住完成签到,获得积分10
2秒前
qq完成签到,获得积分10
2秒前
Jarvi发布了新的文献求助10
2秒前
烤鸭完成签到 ,获得积分10
3秒前
zimablue发布了新的文献求助10
3秒前
祝愿完成签到,获得积分10
4秒前
旦皋发布了新的文献求助10
4秒前
4秒前
烟花应助啵萝味儿的奶盖采纳,获得10
5秒前
vincentbioinfo完成签到,获得积分10
5秒前
WJH发布了新的文献求助10
5秒前
量子星尘发布了新的文献求助10
7秒前
12we完成签到 ,获得积分10
8秒前
8秒前
9秒前
学不懂数学应助茶茶采纳,获得20
9秒前
隐形曼青应助旧辞采纳,获得10
9秒前
何佳完成签到,获得积分10
10秒前
烟花应助coco采纳,获得10
10秒前
小晶完成签到,获得积分10
10秒前
zimablue完成签到,获得积分10
11秒前
慕青应助范先生采纳,获得10
11秒前
zzz完成签到,获得积分10
12秒前
13秒前
海盗船长完成签到,获得积分10
13秒前
等待寄云完成签到 ,获得积分10
13秒前
酷波er应助王冉冉采纳,获得10
14秒前
lcjynwe完成签到,获得积分10
15秒前
新奇完成签到 ,获得积分10
15秒前
Misty_发布了新的文献求助10
15秒前
iNk应助不会取名字采纳,获得20
15秒前
Orange应助Hannes采纳,获得10
15秒前
17秒前
多多少少忖测的情完成签到,获得积分10
17秒前
小马甲应助lx采纳,获得10
17秒前
18秒前
阔达冰兰发布了新的文献求助10
18秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038524
求助须知:如何正确求助?哪些是违规求助? 3576221
关于积分的说明 11374737
捐赠科研通 3305912
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892688
科研通“疑难数据库(出版商)”最低求助积分说明 815048